🇺🇸 FDA
Patent

US 11266720

Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

granted A61KA61K38/37A61K47/643

Quick answer

US patent 11266720 (Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof) held by BIOVERATIV THERAPEUTICS INC. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
64
CPC classes
A61K, A61K38/37, A61K47/643, A61K47/6811, A61P